SIVASTIN 28CPR RIV 40mg
SIMVASTATIN Active Group
modified substances therapeutic lipids, unbound
Product Type DRUG-FREE NHS scheme ETHICS FOR DISEASE
Class A Recipe Type RR - Repeat
Form Farm. COATED TABLETS BLISTER Container Data Commerc
valid for 24 months. 19/10/2004 Price
ATC C10AA01
The product contains no gluten gluten
Manufacturer SIGMATAU IND.FARM.RIUNITE SpA
Pharmacotherapeutic
lipid modified substances, not associated. INDICATIONS
hypercholesterolaemia. Treatment of hypercholesterolemia primary or de lla
mixed dyslipidaemia, as an adjunct to diet when the TA said
to diet and other non-pharmacological treatments (eg
physical exercise, weight reduction) and 'inadequate.
treatment of homozygous familial hypercholesterolemia as an adjunct to diet and
other lipid-lowering treatments (eg LDL apheresis) or if such treatments are not appropriate
catkins. Cardiovascular prevention. Reduction of mortality
lla 'and morbidity' in patients with cardiovascular bad
ttia atherosclerotic cardiovascular disease or diabetes mellitus,
normal or increased cholesterol levels, as a carrier for co
rrezione other factors risk and other cardioprotective therapy
there.
CONTRAINDICATIONS / EFF.SECONDAR
hypersensitivity 'to simvastatin or to any of the excipients
. Active liver disease or persistent elevations of serum transamination
asi no obvious cause. Pregnancy and lactation. Somminis
traction concomitant potent CYP3A4 inhibitors (eg. Itracon
azole, ketoconazole, HIV protease inhibitors, erythromycin,
clarithromycin, telithromycin and nefazodone). E '
contraindicated during pregnancy. The safety in pregnant women is not 'was st
skills. There have been no controlled clinical studies in women simvast
atina in pregnancy. I have received reports of
rare congenital anomalies following intrauterine exposure to
Itor inhibitor of HMG-CoA reductase. However, in a prospective analysis of
about 200 pregnancies exposed during the first quarter of
SIVASTIN or another inhibitor of HMG-CoA reductase inhibitors closely related, the
'incidence of congenital anomalies and' comparable to that served in the os
general population. This number of pregnancies and '
is statistically sufficient to exclude an increase in congenital anomalies
equal to or greater than 2.5 times the background incidence.
Although there is no evidence that the incidence of congenital abnormalities
ite in the offspring of patients or other HMG-CoA reductase
closely related it differs from that observed
lla general population, maternal treatment can '
reduce the fetal levels of mevalonate, a precursor of cholesterol biosynthesis cole
. Atherosclerosis and 'a chronic process, and ordinarily
inter ruption of lipid-lowering drugs during pregnancy should ave re
a limited impact on long-term risk associated with the ip
ercolesterolemia primary. For these reasons, should not be used n the
pregnant women who wish to become pregnant or suspect
pregnant. Treatment should be discontinued
for the duration of pregnancy or until it has been determined that the woman on and
n 'pregnant. It 's not known whether simvastatin or its metabolit
is excreted in breast milk. Because 'many drugs are exc
networks in breast milk and since' reactions may occur if adversaries
series, women who take it should not breastfeed.
DOSAGE The dosage range and '5-80 mg / day given orally
single dose in the evening. Dosage adjustments, if required,
should be made at intervals of not less than 4 weeks
up to a maximum of 80 mg / day administered as a single dose in the evening. The dosage of the
80 mg, and 'only recommended in patients with severe ipercolester
Olema and high risk of cardiovascular complications. Iperc
olesterolemia. The patient should be placed on a cholesterol-lowering diet standa rd
and should continue on this diet during treatment
chin. The starting dose and 'usually 10-20 mg / day administered as a single dose
ato in the evening. Patients for whom it is' necessary
to a large reduction in LDL-C (greater than 45%) can start with 2
0-40 mg / day given in single dose in the evening.
dosage adjustments, if required, should be made as specified
s deed. Homozygous familial hypercholesterolemia. Based on the results
of a controlled clinical study, the recommended dosage and '40 mg /
day in the evening or 80 mg / day in three divided doses of 20 mg, 20 mg, and a
evening dose of 40 mg. In these patients must be used
adjunct to other lipid-lowering treatments (eg. LDL apheresis) or if
these treatments are not available. Prevention of cardiovascular
king. The usual dose is' from 20 to 40 mg / day given in one dose
ÑGOL the evening in patients at high risk of coronary heart disease
(CHD, with or without hyperlipidaemia). Drug therapy can '
be started simultaneously with diet and exercise. The contracting
displacements of dosage, if necessary, should be performed as specified above
certificate. Concomitant therapy. E 'effective alone or in association with one
bile acid sequestrants. The administration must take place
ne or> 2 hours before or> 4 hours after administration of a bile acid sequestration
ante. For patients taking cyclosporine, from
nazolo, gemfibrozil, other fibrates (except fenofibrate) or niacin
a lipid-lowering doses (> 1 g / day) concurrently with SIVASTIN, d
osaggio SIVASTIN not to exceed 10 mg / day. In patients ass
Umon amiodarone or verapamil concomitantly with SIVASTIN, the dosage of the
SIVASTIN should not exceed 20 mg / day. Dosage in
impairment. Do not require adjustments in dosage in patients with moderate renal insufficiency
. In patients with renal
g rave (creatinine clearance < 30 ml/ min), dosaggi superiori a 10
/ mg day should be carefully assessed and, if deemed necessary,
cautiously. Use in the elderly.
contracting are not required displacements of the assay. Use in children and adolescents . The effective
to and safe use in children has not been established. It 's not
recommended for use in children.
INTERACTIONS Interactions with lipid-lowering drugs that can cause myopathy q
hen administered alone. The risk of myopathy, including rabdom
iolisi, is increased during concomitant administration
with fibrates and niacin (nicotinic acid) (> = 1 g / day). In addition, there '
a pharmacokinetic interaction with gemfibrozil leading to an increase
to plasma levels of simvastatin. When simvastatin and fenof
ibrato are administered concomitantly, and there '
evidence that the risk of myopathy exceeds the sum of individual risks
onnessi c to each of the two drugs. For other fibrates are not dis
ponibili appropriate pharmacovigilance data and pharmacokinetics.
effects of other drugs on simvastatin. Interaction with CYP3A4. The sim
vastatina and 'a substrate of cytochrome P450 3A4. Potent inhibitors of cytochrome P450 3A4
increase the risk of myopathy and rhabdomyolysis
increasing the concentration of activity 'of HMG-CoA reductase
in plasma during simvastatin therapy. These include the
NiBiTor itraconazole, ketoconazole, erythromycin, claritrom
icina, telithromycin, HIV protease inhibitors, and nefazodone.
Coadministration of itraconazole resulted in an increase of more than
more 'than 10 times the exposure to simvasta
tina acid (the active metabolite beta-hydroxy acid).
Telithromycin caused an increase equal to 11 times the exposure to simvas
tatina acid. Therefore, combination with itraconazole, ketoconazole,
HIV protease inhibitors, erythromycin, clarithromycin, and nefazodone and towels
tromicina 'contraindicated. If treatment with iTRAC
nazolo, ketoconazole, erythromycin, clarithromycin or telithromycin
and 'unavoidable, therapy with simvastatin should be suspended in my heart I know
treatment. We must act with caution when combining with some other simvas
tatina less potent CYP3A4 inhibitors: ciclosporin
to, verapamil, diltiazem. Cyclosporine. The risk of myopathy / rabdomio
lysis and 'increased by concomitant administration of cyclosporine
particularly at doses more' high levels of simvastatin. The assay
of simvastatin should not exceed 10 mg / day in patients receiving concomitant therapy with cyclosporine
you. Although the mechanism is not to
is fully understood, cyclosporine has been shown to increase the '
AUC of HMG-CoA reductase. The increase in AUC for simvastatin acid and
'presumably due, in part, to
and CYP3A4. Danazol: The risk of myopathy and rhabdomyolysis 'Committee
increased by concomitant administration of danazol at a dose more' high
of simvastatin. Gemfibrozil. Gemfibrozil increases the AUC of sim
vastatina acid by 1.9-fold, possibly due to inhibition of the glucuronidation pathway
. Amiodarone and verapamil. The risk of rhabdomyolysis and iopatia
m '
and increased by concomitant administration of amiodarone or verapamil with doses more' high levels of simvastatin.
In an ongoing clinical trial, and 'was reported in 6% of patients
patients treated with simvastatin 80 mg and amiodarone.
analysis of available clinical trials showed an incidence of myopathy circ
to 1% in patients treated with simvastatin 40 mg or 80 mg and the verapam
. In a pharmacokinetic study, coadministration
with verapamil resulted in an increase of 2.3 times the position of Ex
simvastatin acid, presumably due, in part, of
ell'inibizione CYP3A4. The dose of simvastatin should not therefore de
to exceed 20 mg / day in patients receiving concomitant amiod
arone or verapamil, unless the clinical benefit is verosimilme
nte outweigh the increased risk of myopathy and rhabdomyolysis. D
iltiazem. An analysis of available clinical trials showed an injection
1% incidence of myopathy in patients treated with simvastatin 80 mg and diltiazem
. The risk of myopathy in patients taking 40 mg mvastatina
is not 'was increased by diltiazem Conco
mitanza. In a pharmacokinetic study, concomitant administration of diltiazem before
caused a 2.7-fold increase
in exposure to simvastatin acid, presumably due to inhibition of CYP 3A4
. The dose of simvastatin should not exceed 40 mg /
and in patients with concomitant diltiazem, unless the clinical well
EFIC is likely to outweigh the increased risk of myopathy and rhabdomyolysis or
. Grapefruit juice. Grapefruit juice inhibits cytochrome P450 3A4
. Concomitant simvastat
ine and large amounts '(more' of a liter per day) of grapefruit juice
mo resulted in a 7-fold increase in exposure to SIMV
statin acid. Intake of 240 ml of grapefruit juice and simvastatin to but
ttino in the evening resulted in an increase of 1.9 volts
e. The intake of grapefruit juice during treatment with simvas
tatina should therefore be avoided.
Effects of simvastatin on the pharmacokinetics of other drugs. Simvastatin has no effect on cytochrome P450 3A4
ibitorio. It's not 'Therefore, simvastatin
of simvastatin on plasma concentrations of metabolic substances used does
via cytochrome P450 3A4. Oral anticoagulants.
in two clinical studies, one in normal volunteers and the other in patients ipercol
esterolemici, simvastatin 20-40 mg / day had a modest effect
enhancement of coumarin anticoagulants: the time of prothrombotic
bina, reported as International Normalized Ratio (INR) and 'increased
a baseline of 1.7 to 1.8 and from a baseline of 2.6 to 3.4 in the volunteer and patient studies
, respectively. There have been reports of rare mol
to elevated INR. In patients treated with anticoagulants Cumar
Inici the prothrombin time should be determined before starting treatment with simvastatin
king and frequently enough in my heart I know
of early therapy to ensure that there is no change happens during ver
significant prothrombin time. A
time documented a stable prothrombin time, time protromb
ina can be monitored at the intervals recommended abitualment
and for patients on coumarin anticoagulants. If the dosage of simvastatin Thurs
is changed or discontinued
you must repeat the same procedure. Simvastatin therapy has not 'been Associat
aa bleeding or with changes in prothrombin time in patients
are not taking anticoagulants.
SIDE EFFECTS
The frequencies of the following adverse events, reported during
s Tubes clinical and / or post-marketing use,
are classified on the basis of the assessment of their incidence rates in large, clinical studies
long-term placebo-controlled, including HPS and 4S
with 20,536 and 4,444 patients respectively (See section 5.1). P er
HPS were recorded only serious adverse events as well as myalgia
a, elevated serum transaminases and CK. For 4S
were recorded all the adverse events listed below. If rates of the
IMPLICATION on simvastatin were less than or similar to this
lli of placebo in these trials, and there were reports of spontaneous institutions ev
reasonably be classified as related to rap
rto of causality ', these adverse events
were classified as rare. In HPS (see section 5.1) on 20,536 patients treated with S
IVASTIN 40 mg / day (n = 10,269) or placebo (n = 10,267), the profiles of s afety
were comparable between patients treated with SIVASTI
N 40 mg and placebo in the 5-year average duration of study
llo. The rates of treatment discontinuation due to side effects
were comparable (4.8% in patients treated c
SIVASTIN on 40 mg compared to 5.1% in patients treated with placebo)
. The incidence of myopathy and 'was less than 0.1% in patients
t SIVASTIN rats with 40 mg. There were high levels of between
nsaminasi (over 3 times the upper limit of normal with
with stops through repeated tests) 0.21% (n = 21) among patients with
ttati SIVASTIN 40 mg compared to 0, 09% (n = 9) of patients t
rats with placebo. The frequencies of adverse events are ranked
s ccording to the following: Very common (> 1 / 10), common (> = 1 / 100, <
1 / 10), uncommon (> = 1,1000, < 1/100), raro (> = 1 / 10,000, < 1/1.000)
, very rare (< 1/10.000) incluse segnalazioni isolate. Alterazioni de
the blood and lymphatic system: Rare: anemia.
n ervoso system disorders: Rare: headache, paresthesia, dizziness, peripheral neuropathy.
saved Rev Gastrointestinal: Rare: constipation, abdominal pain, bloating ,
dyspepsia, diarrhea, nausea, vomiting, pancreatitis.
Hepatobiliary disorders: Rare: hepatitis / jaundice. Skin and subcutaneous tissue disorders: Rare: rash, pruritic
or alopecia. Musculoskeletal, connective tissue and bone
: Rare: myopathy, rhabdomyolysis, myalgia, muscle cramps. Disorderly
nationals and general disorders and administration site conditions: Rare: asthenia
a. It 'been reported rarely an apparent hypersensitivity syndrome
eng' which included some of the following features: angioedema,
lupus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis
you, thrombocytopenia, eosinophilia, elevated ESR, arthritis and artral
already, urticaria, photosensitivity ', fever, flushing, dyspnea and malaise
. Search: Rare: elevated serum transaminases (alanine aminotr
ansferasi, aspartate aminotransferase, gamma-glutamyl transpeptidase),
increases in alkaline phosphatase increased levels of serum CK
a.
0 comments:
Post a Comment